Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida
- Wednesday, March 23, 2022, 7:07
- Finance
- Add a comment
Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO, March 23, 2022 /PRNewswire/ — Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing…
About the Author
adminasapcorp has written 41789 stories on this site.